NEW YORK (GenomeWeb) – Israeli biotech firm MeMed said that it has won a €2.3 million ($2.6 million) grant from the European Commission to support clinical testing of its ImmunoXpert test, a protein diagnostic for distinguishing between bacterial and viral infections.
According to the company, the funds will be used to put the test in pediatric departments in Italy and Germany. It aims to monitor 1,200 children with either respiratory tract infections or fevers without source, assessing both the clinical utility and cost-effectiveness of the test.
The ImmunoXpert test uses a three-protein signature to determine whether a person has a bacterial or viral infection, helping physicians choose appropriate treatment.
MeMed previously received awards of €6 million and €3 million from the EC for development of the test, which it has launched on an early-access basis in the EU, Switzerland, and Israel.